176 related articles for article (PubMed ID: 14755895)
1. Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores SA
Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
[TBL] [Abstract][Full Text] [Related]
2. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
4. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting angiogenesis in retinoblastoma.
Apte RS; Harbour JW
Ophthalmic Res; 2007; 39(4):188-90. PubMed ID: 17556838
[No Abstract] [Full Text] [Related]
6. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives].
Holz FG; Miller DW
Ophthalmologe; 2003 Feb; 100(2):97-103. PubMed ID: 12589452
[TBL] [Abstract][Full Text] [Related]
8. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
9. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
Michels S; Rosenfeld PJ
Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
[TBL] [Abstract][Full Text] [Related]
11. Ruboxistaurin (Eli Lilly).
Wheeler GD
IDrugs; 2003 Feb; 6(2):159-63. PubMed ID: 12789620
[TBL] [Abstract][Full Text] [Related]
12. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration.
Moshfeghi AA; Puliafito CA
Expert Opin Investig Drugs; 2005 May; 14(5):671-82. PubMed ID: 15926872
[TBL] [Abstract][Full Text] [Related]
13. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic phytochemicals and medicinal herbs.
Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
[TBL] [Abstract][Full Text] [Related]
15. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
16. PTK/ZK (Novartis).
Drevs J
IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
[TBL] [Abstract][Full Text] [Related]
17. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
18. Monitoring ocular drug therapy by analysis of aqueous samples.
Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
[TBL] [Abstract][Full Text] [Related]
19. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
Wong TY
Am J Ophthalmol; 2009 Sep; 148(3):327-9. PubMed ID: 19703607
[No Abstract] [Full Text] [Related]
20. Ocular drug development--future directions.
Sherris D
Angiogenesis; 2007; 10(2):71-6. PubMed ID: 17372850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
